New executive leadership and CEO at BiPar Sciences
BiPar chief executive officer and president Hoyoung Huh, M.D., Ph.D. will take on a broader role in the sanofi-aventis organization as Chairman of the Board of Directors of BiPar, as well as chair of the newly formed BiPar Innovation Board. As part of this new role, Dr. Huh will serve as advisor to sanofi-aventis Chief Executive Officer Christopher A. Viehbacher and to Executive Vice President Research and Development Marc Cluzel, as well as to the Executive Committee, in the areas of innovation, R&D transformation, and entrepreneurship.
Sanofi-aventis has appointed Atul Dhir, M.D., Ph.D. as Chief Executive Officer of BiPar Sciences effective December 1, 2009. Dr. Dhir's mission is to continue developing the innovative BiPar portfolio, including the ongoing clinical program of BSI-201 - which, of an emerging class of investigational compounds (PARP inhibitors), is currently the furthest along in the Phase 3 clinical development in the metastatic triple negative breast cancer setting. ■